Figure 3.
Incidence of (A) allograft loss due to all causes and (B) allograft loss due to TMA after kidney transplantation with therapeutic eculizumab.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.